SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Democratic gains in the midterms are driving intense debate over the market outlook, with traders concerned about possible data-center and AI regulation, tax changes, and political uncertainty. Others argue the result is already priced in and that divided government could limit policy changes, pointing to a sharp rebound in futures after the initial selloff.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Projected Democratic control of Congress is the dominant catalyst, with traders viewing the midterm losses as a major political setback for Trump and many expressing bearish sentiment on DJT amid speculation about investigations and a weakened agenda. Some argue congressional gridlock could limit policy changes, but the conversation is largely focused on the elections implications for Trump and the company.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Democratic gains in Congress are driving debate over QQQ: some traders fear tighter AI and data-center rules could weigh on the tech-heavy Nasdaq, while others see gridlock and reduced uncertainty as supportive. The community is split after a sharp selloff and rebound, with dip-buyers calling it a relief move and bears warning of further tech weakness.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

Democratic election gains, including in Texas, are driving concern that SpaceX could face greater scrutiny of Musks government ties, contracts, data-center plans, and a possible Tesla merger. Traders disagree on the impact: some expect political headwinds, while others argue the projects can proceed and view the weakness as a buying opportunity.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Apples warning that memory prices are rising and expected to keep climbing has renewed bullish interest in SanDisk and other memory stocks, with traders viewing it as evidence of tight supply and pricing strength. The rebound is contested, as many remain wary of the sectors sharp recent swings and question whether AI-related demand can offset memorys cyclical risks.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros blowout quarterly results and higher full-year outlook, driven by strong AI-server demand, are the main focus. Traders are upbeat about growth and the new guidance but debate whether thin margins and lingering confidence concerns justify the muted, volatile share reaction.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is drawing attention over traders reaction to perceived Democratic gains in the elections and Elon Musks political involvement. Many fear added scrutiny of Musks companies, reduced government support, and complications for a possible SpaceX merger, while some argue EV policies could benefit Tesla or view the selloff as a buying opportunity.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

A letter from 28 HOPE-3 investigators urging FDA approval of Capricors deramiocel and challenging the agencys interpretation of the trial data has renewed attention ahead of the FDA decision on the Duchenne muscular dystrophy therapy. Traders are largely optimistic that the letter strengthens the approval case, while some remain cautious about the FDAs concerns; speculation about short covering is also fueling the rally, but approval is uncertain.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL swung sharply as Democratic election gains sparked fears of tighter data-center rules and slower AI infrastructure spending, weighing on semiconductor stocks. Traders debated whether the selloff was an overreaction, while chip shares rebounded with election uncertainty easing and AMD and SMCI results supporting sentiment.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles stock-and-bond financing for its AI data-center expansion is driving debate over dilution, borrowing costs and whether future cloud revenue will generate enough cash to justify the spending. Some traders view the completed fundraising and share-price rebound as easing the overhang, while others remain concerned about debt and further downside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Waters Q3 Earnings & Revenues Beat Estimates, 2026 Guidance Raised

WAT beats Q3 2026 earnings and revenue estimates, fueled by acquisitions and strong organic growth and raises its full-year revenue and earnings outlook.

Merit Acquires Solo Pace For $45 Mln; Shares Down

(RTTNews) - Merit Medical Systems (MMSI) acquired Solo Pace, Inc., a Minneapolis-based manufacturer of temporary pacing technology used to treat patients with aortic stenosis. Merit, which had previously invested in Solo Pace, purchased the remaining shares on October 13, 2026, f...

DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise

DXCM shares rise as Q3 earnings and revenues beat estimates, margins expand and 2026 guidance improves, driven by strong U.S. demand and G7 15 Day adoption.

These Analysts Boost Their Forecasts On Merit Medical Systems After Strong Q3 Results

Merit Medical beat Q3 estimates, raised FY2026 EPS guidance, narrowed sales outlook; analysts lifted price targets to $110 and $106.read more...

Merit Medical (MMSI) Q3 Earnings and Revenues Beat Estimates

Merit Medical (MMSI) delivered earnings and revenue surprises of +7.69% and +1.43%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Merit Medical Systems Q3 2026 Earnings Call Transcript

Merit Medical Systems (NASDAQ:MMSI) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you byread more...

Merit Medical (MMSI) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Merit Medical (MMSI) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Reasons to Hold Hinge Health Stock in Your Portfolio for Now

HNGE's strong revenue growth, raised 2026 outlook and expansion into Migraine and GI care support its growth prospects despite investment pressures.

Ecolab Q3 Earnings In-Line With Estimates, Revenues Increase Y/Y

ECL's Q3 earnings increase 5% to $2.18 per share, while revenues jump 13%, driven by strong Water and Life Sciences growth and accelerating digital sales.

Here's Why You Should Hold PacBio Stock in Your Portfolio for Now

PACB's growing clinical adoption, advanced sequencing technologies and rising consumables sales support growth, but funding headwinds and margin pressures persist.

Merit Medical Systems, Inc. engages in the manufacture and marketing of proprietary disposable medical devices. It operates through the Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups. The Endoscopy segment integrates non-vascular stent technology with balloon dilators, inflation devices, guide wires, procedure kits, and other devices that are used by gastroenterologists, endoscopists, pulmonologists, and thoracic and general surgeons. The company was founded by Fred P. Lampropoulos, Darla Gill, Kent W. Stanger, and William Padilla in July 1987 and is headquartered in South Jordan, UT.

Merit Medical Systems, Inc.

Merit Medical Stock Soars After Hours As Better-Than-Expected Q2 Guidance Outweighs CEO Exit

Equity

Neutral Sentiment

Merit Medical shares edged higher in Monday’s after-hours session after the company&nbsp;guided to stronger-than-expected revenue for the second quarter and outlined plans for a new CEO later this year.The company rose 3.2% after hours to $94.01, trimming losses from the regular session, where it closed down 2.6% at $91.12.For the three months through June, Merit estimates revenue between $380 million and $384 million, representing a 12% to 14% increase from the same period last year.&nbsp;Adjusting for currency fluctuations, the company expects growth to range between 11% and 13%, with approximately $2.3 million in revenue being shaved off due to exchange rate impacts. A year earlier, Merit posted $338 million in revenue.&nbsp;The latest results&nbsp;exceeded analysts’ expectations, which had projected a figure of $372.47 million. A leadership handoff is also scheduled for later this year.&nbsp;On Oct. 3, Martha Aronson is set to take over as president and CEO, replacing Fred P. Lampropoulos, who will continue as chairman of the board. The transition follows a board-led selection process.&nbsp;Lampropoulos will remain in his current executive role until the transition date. Aronson held senior roles at Ecolab and Hill-Rom Holdings, and spent&nbsp;nearly 20 years at Medtronic, managing business operations in both domestic and global markets.&nbsp;She has also served on the boards of several healthcare and medtech firms, including Conmed Corporation, where she was chair, as well as Methode Electronics and Cardiovascular Systems, Inc.On Stocktwits, the retail sentiment&nbsp;for&nbsp;<a href="https://stocktwits.com/symbol/MMSI">MMIS stock</a> was ‘neutral’ amid ‘low’ message volume&nbsp;late Monday.Merit Medical’s stock has declined 5.2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The company expects second-quarter revenue to grow by as much as 14% year-over-year, with foreign exchange headwinds expected to trim approximately $2.3 million from the top line.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$1.11	--	--	N/A
Q3 '26	$1.04	$1.12	7.77%	BEAT
Q2 '26	$0.96	$1.19	24.09%	BEAT
Q1 '26	$0.83	$0.94	12.85%	BEAT
Q4 '25	$0.95	$1.04	8.98%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

MMSI Earnings

Latest Earnings Results: Q3 '26

Historical Earnings